M
Mark Versavel
Researcher at Pfizer
Publications - 13
Citations - 1503
Mark Versavel is an academic researcher from Pfizer. The author has contributed to research in topics: Placebo & Ziprasidone. The author has an hindex of 10, co-authored 13 publications receiving 1393 citations.
Papers
More filters
Journal ArticleDOI
Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial
Rainer Sabatowski,Rafael Gálvez,David A. Cherry,Florence Jacquot,Emmanuelle Vincent,Pascal Maisonobe,Mark Versavel +6 more
TL;DR: Health‐related quality‐of‐life (HRQoL) measurements using the SF‐36 Health Survey demonstrated improvement in the mental health domain for both pregabalin dosages, and bodily pain and vitality domains were improved in the 300 mg/day group.
Journal ArticleDOI
Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial.
Robert van Seventer,Hilary A. Feister,James P. Young,Malcolm John Stoker,Mark Versavel,Laurence Rigaudy +5 more
TL;DR: Pregabalin, dosed BID, reduced neuropathic pain associated with PHN and was well tolerated; it also reduced the extent to which pain interfered with sleep.
Journal ArticleDOI
Patient phenotyping in clinical trials of chronic pain treatments: IMMPACT recommendations.
Robert R. Edwards,Robert H. Dworkin,Dennis C. Turk,Martin S. Angst,Raymond A. Dionne,Roy Freeman,Per Hansson,Simon Haroutounian,Lars Arendt-Nielsen,Nadine Attal,R. Baron,Joanna M. Brell,Shay Bujanover,Laurie B. Burke,Daniel B. Carr,Amy S. Chappell,Penney Cowan,Mila Etropolski,Roger B. Fillingim,Jennifer S. Gewandter,Nathaniel P. Katz,Ernest A. Kopecky,John D. Markman,George G. Nomikos,Linda Porter,Bob A. Rappaport,Andrew S.C. Rice,Joseph M. Scavone,Joachim Scholz,Lee S. Simon,Shannon M. Smith,Jeffrey Tobias,Tina Tockarshewsky,Christine Veasley,Mark Versavel,Ajay D. Wasan,Warren Wen,David Yarnitsky +37 more
TL;DR: Evidence is presented on the most promising phenotypic characteristics of patients that are most predictive of individual variation in analgesic treatment outcomes, and the measurement tools that are best suited to evaluate these characteristics.
Journal ArticleDOI
Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study.
TL;DR: An investigation of the efficacy and safety of twice daily pregabalin enrolled 395 adults with painful DPN for ≥1 year in a 12‐week, double‐blind, placebo‐controlled trial.
Journal ArticleDOI
Ziprasidone Plus a Mood Stabilizer in Subjects With Bipolar I Disorder: A 6-Month, Randomized, Placebo-Controlled, Double-Blind Trial
Charles L. Bowden,Eduard Vieta,Kathleen S. Ice,Jeffrey H. Schwartz,Paul P. Wang,Mark Versavel +5 more
TL;DR: Ziprasidone is an effective, safe, and well-tolerated adjunctive treatment with a mood stabilizer for long-term maintenance treatment of bipolar mania.